UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043591
Receipt number R000049775
Scientific Title An exploratory study of the relationship between pharmacokinetics of melphalan and early post-hematopoietic stem cell transplant complications in allogeneic transplantation using conditioning regimen consisting of fludarabine, cytarabine, melphalan, and low-dose total body irradiation
Date of disclosure of the study information 2021/03/12
Last modified on 2021/09/10 15:39:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Relationship between pharmacokinetics of melphalan and early post-hematopoietic stem cell transplant complications

Acronym

SCT-MEL-AUC20

Scientific Title

An exploratory study of the relationship between pharmacokinetics of melphalan and early post-hematopoietic stem cell transplant complications in allogeneic transplantation using conditioning regimen consisting of fludarabine, cytarabine, melphalan, and low-dose total body irradiation

Scientific Title:Acronym

SCT-MEL-AUC20

Region

Japan


Condition

Condition

Acute myelogenous leukemia

Classification by specialty

Pediatrics

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To obtain basic data on the pharmacokinetics of melphalan in children undergoing allogeneic hematopoietic stem cell transplantation and its relationship to early post-transplant complications

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Relationship between melphalan-AUC and the frequency of CTC-AE grade 3 or higher for dysphagia and diarrhea up to 28 days after transplantation

Key secondary outcomes

1) Melphalan clearance
2) A relationship between melphalan-AUC and the following parameters:
i) age, dose per body weight, pre-transplant Creatinine (Cr), 24-hour Cr clearance, Cystatin-C, and eGFR.
ii) Maximum Cr value, minimum eGFR estimated from Cr up to 28 days after transplantation
iii) First day of febrile neutropenia and number of days with fever up to 28 days after transplantation
iv) First day of opioid use and duration of opioid use up to 28 days after transplantation
3) After completion of the primary analysis of the AML-SCT15 study, the relationship with cumulative incidence of relapse and leukemia-free survival will also be examined.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

20 years-old >

Gender

Male and Female

Key inclusion criteria

Patients enrolled in AML-SCT15 at a facility participating in the Japan children cancer Group (JCCG) subcommittee on hematological malignancies (JPLSG) who plan to undergo allogeneic transplantation using the FLAMEL regimen and who have obtained written consent from a surrogate for participation in this study

Key exclusion criteria

Patients with any other inappropriate status judged by physician

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Ishida
Middle name
Last name Hiroyuki

Organization

Kyoto City Hospital

Division name

Department of Pediatrics

Zip code

604-8845

Address

1-2, Higashitakada-cho, Mibu, Nakagyou-ku, Kyoto

TEL

075-311-5311

Email

ishidah@koto.kpu-m.ac.jp


Public contact

Name of contact person

1st name Ishida
Middle name
Last name Hiroyuki

Organization

Kyoto City Hospital

Division name

Department of Pediatrics

Zip code

604-8845

Address

1-2, Higashitakada-cho, Mibu, Nakagyou-ku, Kyoto

TEL

075-311-5311

Homepage URL


Email

ishidah@koto.kpu-m.ac.jp


Sponsor or person

Institute

Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Stem cell transplantation committee

Institute

Department

Personal name



Funding Source

Organization

Gold Ribbon Network

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto City Hospital

Address

1-2, Higashitakada-cho, Mibu, Nakagyou-ku, Kyoto

Tel

075-311-5311

Email

nfujita@kch-org.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 11 Month 06 Day

Date of IRB

2020 Year 12 Month 16 Day

Anticipated trial start date

2021 Year 01 Month 12 Day

Last follow-up date

2022 Year 10 Month 30 Day

Date of closure to data entry

2022 Year 12 Month 20 Day

Date trial data considered complete

2022 Year 12 Month 20 Day

Date analysis concluded

2023 Year 12 Month 31 Day


Other

Other related information

Return of melphalan pharmacokinetic to the attending physician


Management information

Registered date

2021 Year 03 Month 11 Day

Last modified on

2021 Year 09 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049775


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name